Cristina Vigilante, Prashansa Daga, Adam Russell, Rohan Muralee, Darrick Cheung
The COVID-19 pandemic is an unprecedented crisis with virtually no point of reference in modern history. Organizations are struggling to keep pace in responding to the constantly-evolving situation.
The Life Sciences industry has been experiencing mixed fortunes, with developments creating new threats and opportunities at the same time. Its experience has been unlike that in many other industries which have experienced impacts that are more pronounced, whether positive or negative.
Many firms are scrambling to develop tests, vaccines, and treatments for COVID-19, while also trying to advance treatments across therapeutics areas, secure supply, safeguard employee well-being, ensure business continuity, and drive innovation in other areas. These unique circumstances demand tailored mitigation measures that can only be appreciated by people familiar with the way the industry operates and the challenges it faces.